Skip to main content
. Author manuscript; available in PMC: 2014 Sep 11.
Published in final edited form as: N Engl J Med. 2014 Jan 22;370(11):997–1007. doi: 10.1056/NEJMoa1315226

Figure 1. Progression-free and Overall Survival.

Figure 1

At the time the study was stopped, the median duration of progression-free survival among 110 patients receiving idelalisib and rituximab had not yet been reached; among the 110 patients receiving placebo and rituximab, the median duration of progression-free survival was 5.5 months (hazard ratio for progression or death in the idelalisib group, 0.15; 95% confidence interval [CI], 0.08 to 0.28; P<0.001) (Panel A). The median duration of overall survival in the two study groups had also not been reached; the overall survival rate was 92% in the idelalisib group versus 80% in the placebo group at 12 months (hazard ratio for death, 0.28; 95% CI, 0.09 to 0.86; P = 0.02) (Panel B).